PubMed Health⌕ Search

Biomedical subjects

S Merli

Publications and source records attributed to S Merli.

36 records · Page 2Linked to original sources
PubMed1980

New anthracycline glycosides from Micromonospora. I. Description of the producing strain.

During the course of successive mutagenic treatments of Streptomyces peucetius var. caesius, producer of anthracyclines, a novel mutant was isolated from a plate of the surviving population. This mutant showed remarkable morphological, cultural and biochemical differences when compared to the original strain. The new culture produced four new glycosides of a novel class within the group of the daunorubicin related anthracyclines, two of which were also present in the original strain. To our surprise the taxonomical study carried out on this mutant allowed its assignment to the genus Micromonospora ORSKOVA (1923). The possibilities of whether this new strain has originated from a contamination or from a mutation are discussed. The type strain is Micromonospora sp. strain B211 F.I. (identical to ATCC 31366; DSM 1190; FRI 4363).

Antibiotics, Antineoplastic↗
PubMedDate not supplied

13-Deoxycarminomycin, a new biosynthetic anthracycline.

A new antitumor antibiotic, 13-deoxycarminomycin, has been isolated from the anthracycline complex produced by Streptomyces peucetius var. carminatus (ATCC 31502), a biochemical mutant of Streptomyces peucetius var. caesius, the doxorubicin-producing microorganism. The new anthracycline, showing antibacterial and cytotoxic activity in vitro, was found active against P-388 murine leukemia.

Animals↗
PubMedDate not supplied

[Proposal for an informed consent form for hormonal replacement therapy in ambulatory care].

Hormonal Replacement Therapy (HRT) represents a valid therapeutic approach for menopausal symptoms and for the prevention of cardiovascular disease and osteoporosis. Nevertheless, an informed consent, after a complete information, must be obtained from the patient. This procedure is generally adopted in any medical activity, but the modality of the consent in the HRT administration is not well established (verbal or written?, timing of administration?). The authors propose an informed written consent model to be utilized in menopausal centers; this model synthetically informs about HRT benefits and risks and must be red and signed by the patient. The written consent should be explained through a verbal detailed discussion about it, during which the patient's comprehension must be assured. The informed consent procedure should be renewed every year in long term-users. The influence of the HRT informed consent in menopausal centers must be analyzed in particular as far as women compliance is concerned.

Adult↗
PubMedDate not supplied

Identification of differentially glycosylated forms of the soluble p75 tumor necrosis factor (TNF) receptor in human urine.

Human urine is known to contain a 30 kDa soluble form of the p75-TNF receptor (sTNF-R2). In this work we have purified sTNF-R2 from the urine of normal subjects and further characterized its structure and activity. sTNF-R2 was resolved by reducing SDS-PAGE in a major band of 30 kDa, similar in size to the previously described urinary sTNFR2, and in a minor band of 45 kDa. "Western" blotting analysis with anti-TNF-R1 and anti-TNF-R2 antibodies showed that both bands were immunologically related to the membrane TNF-R2. Glycosylation studies indicated that the 30 kDa is N-glycosylated while the 45 kDa form is N- and O-glycosylated, and suggested that both forms contain terminally linked sialic acid that is differentially recognized by lectins. These results indicate that human urine contains, besides the 30 kDa form, a new form of 45 kDa characterized by different glycosylation type and degree.

Amidohydrolases↗